Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi, Li Wang, Shu Cheng, Ying Qian, Yan Zhao, Yang He, Hong-Mei Yi, Bin-shen Ou-yang, Xu-Feng Jiang, Biao Li, Qi Song, Rong-Ji Mu, Wei-Li Zhao

Blood (2025) 146 (21): 2561–2573.

https://doi.org/10.1182/blood.2025028649

Published: 2025

Includes: Supplemental data

Journal Articles

Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study

Yu-Ran Qiu, Ming-Ci Cai, Wenyu Li, Haiyan Yang, Jing Wang, Li Wang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3649.

https://doi.org/10.1182/blood-2025-3649

Published: 2025

Journal Articles

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Meng-Meng Ji, Siyuan Chen, Yige Shen, Li Wang, Shu Cheng, Pengpeng Xu, Wei Tang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2025-3732

Published: 2025

Journal Articles

The features of FLT3 internal tandem duplication (ITD) in acute myeloid leukemia (AML) patients and impact on prognosis

Bin Chen, Li Wang, Hong Zhang, Yani Lin, Kun Ru

Blood (2025) 146 (Supplement 1): 7017.

https://doi.org/10.1182/blood-2025-7017

Published: 2025

Journal Articles

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study

Qiuqing Xiang, Minqiu Lu, Bin Chu, Lei Shi, Shan Gao, Lijuan Fang, Mengzhen Wang, Shuangnian Xu, Yan Zhu, Li Wang, Junnan Li, Hua Xue, Li Li, Tingting Duan, Ting Zhang, Li Bao

Blood (2025) 146 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2025-4059

Published: 2025

Journal Articles

Curing Hemoglobin H-Constant Spring through Base Editing of Autologous CD34+ Hematopoietic Stem and Progenitor Cells

Li Wang, Hui Xu, Junbin Liang, Yaoyun Li, Lin Cheng, Ying Luo, Liancheng Huang, Lihong Zeng, Rongrong Luo, Bin Xiao, Meiping Liu, Liping Huang, Zhendong Xiao, Xinhua Zhang, Junjiu Huang

Blood (2025) 146 (Supplement 1): 382.

https://doi.org/10.1182/blood-2025-382

Published: 2025

Journal Articles

The infection spectrum in newly diagnosed Acute Myeloid Leukemia patients treated with venetoclax-based or conventional chemotherapy: A real-world retrospective study

Guilin Ren, Li Wang

Blood (2025) 146 (Supplement 1): 1610.

https://doi.org/10.1182/blood-2025-1610

Published: 2025

Journal Articles

Homoharringtonine added to CLAG regimen improves outcome of pediatric Relapsed/Refractory AML: A multicenter prospective study

Blood (2025) 146 (Supplement 1): 5219.

https://doi.org/10.1182/blood-2025-5219

Published: 2025

Journal Articles

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Blood (2025) 146 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2025-3031

Published: 2025

Journal Articles

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan, Jinghua Zhao, Wen Wu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2025-1746

Published: 2025

Journal Articles

A prospective, multicenter, randomized, controlled clinical trial comparing polatuzumab vedotin, zanubrutinib, lenalidomide, and rituximab (Pola-ZR2) versus zanubrutinib, lenalidomide, and rituximab (ZR2) in the treatment of previously untreated, elderly patients with diffuse large B-cell lymphoma (NCT06522555)

Fan Zhang, Zi-Yang Shi, Qing Shi, Yan Zhu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 3696.

https://doi.org/10.1182/blood-2025-3696

Published: 2025

Journal Articles

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Blood (2025) 146 (Supplement 1): 3689.

https://doi.org/10.1182/blood-2025-3689

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

Blinatumomab following reduced-intensity induction chemotherapy in Chinese children with intermediate- or high-risk B-cell precursor acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 5133.

https://doi.org/10.1182/blood-2025-5133

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Blood (2025) 146 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2025-5122

Published: 2025

Journal Articles

Molecular insights from ctdna dynamics: Monitoring MRD and tracking divergent progression modes and clonal evolution patterns

Jinhua Liang, Yi-Fan Wu, Yi-Lun Ji, Liu-Qing Zhu, Li Wang, Jianyong Li, Xu Wei

Blood (2025) 146 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2025-1889

Published: 2025

Journal Articles

Clinical characteristics and prognosis of therapy-related hematological neoplasms: A single-center retrospective study

Xiao-Ling Guo, Ming-Li Wang, Zi-Yuan Nie, Xiao-Lei Zhang, Jinhai Ren

Blood (2025) 146 (Supplement 1): 6897.

https://doi.org/10.1182/blood-2025-6897

Published: 2025

Journal Articles

Impact of hepatitis b virus infection on long-term prognosis in B-cell lymphoma: A retrospective cohort study

Lin Shen, Wenjing Yang, Li Wang, Mingyue Chen, Wu Lipan Fu Lati, Min Wu, Wensi Qian, Yanhui Xie

Blood (2025) 146 (Supplement 1): 7057.

https://doi.org/10.1182/blood-2025-7057

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

The features of FLT3 internal tandem duplication (ITD) in acute myeloid leukemia (AML) patients and impact on prognosis

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study

Curing Hemoglobin H-Constant Spring through Base Editing of Autologous CD34+ Hematopoietic Stem and Progenitor Cells

The infection spectrum in newly diagnosed Acute Myeloid Leukemia patients treated with venetoclax-based or conventional chemotherapy: A real-world retrospective study

Homoharringtonine added to CLAG regimen improves outcome of pediatric Relapsed/Refractory AML: A multicenter prospective study

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blinatumomab following reduced-intensity induction chemotherapy in Chinese children with intermediate- or high-risk B-cell precursor acute lymphoblastic leukemia

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Molecular insights from ctdna dynamics: Monitoring MRD and tracking divergent progression modes and clonal evolution patterns

Clinical characteristics and prognosis of therapy-related hematological neoplasms: A single-center retrospective study

Impact of hepatitis b virus infection on long-term prognosis in B-cell lymphoma: A retrospective cohort study

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only